Kimia Farma, South Korea’s SungWun building $10.2M API facility in Indonesia


Kimia Farma, which is owned by the Indonesian government, and South Korea’s SungWun Pharmacopia are teaming up to build a $10.2 million API facility expected to begin operations in 2018.

The 16,400-square-foot facility will initially be able to produce 30 tons of 8 types of API for medicines per year with 23 of those tons slotted for export, the Jakarta Post reported. The plant will also produce 7 types of high function chemicals annually for use in cosmetics and food supplements.

The joint venture is called Kimia Farma Sungwun Pharmacopia.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

“At present, the country’s pharmaceutical industry uses around 2,200 types of API,” Rusi Rosman, Kimia Farma’s president director, said. “We aim to produce 50% of them within the next 10 years.”

Additional expansion over the next decade is planned to accommodate the goal set down by Rosman.

Currently, India and China are the two largest suppliers of pharmaceutical raw materials to Indonesia, followed by the U.S. and Europe.

-check out the Jakarta News story

Related article:
B. Braun Medical lands $33M loan to build sterile injection plant in Indonesia

Suggested Articles

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down. 

Drugmakers have speculated about delivering temperature-sensitive vaccines and drugs using drones. Now, Merck & Co. is testing the method. 

Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.